Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03280563 · ClinicalTrials.gov registry record · Phase 1
A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
A Phase 1 study of Breast Neoplasms, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 20
- Study locations
NCT03280563 is a Phase 1 study of Breast Neoplasms that has completed, run by Hoffmann-La Roche. The registered enrollment target is 144 participants, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT03280563, a Phase 1 study of Breast Neoplasms, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following treatment with a cyclin-dependent kinase (CDK) 4/6 inhibitor in the first- or second-line setting, such as palbociclib, ribociclib, or abemaciclib. The study will be performed in two stages. During Stage 1, participants will be randomized to fulvestrant (control) or an atezolizumab-containing doublet or triplet combination. Those who experience disease progression, loss of clinical benefit, or unacceptable toxicity may be eligible to receive a new triplet combination treatment in Stage 2 until loss of clinical benefit or unacceptable toxicity. New treatment arms may be added and/or existing treatment arms may be closed during the course of the study on the basis of ongoing clinical efficacy and safety as well as the current treatments available.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Exemestane
- DRUG Fulvestrant
- DRUG Entinostat
- DRUG Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Study Locations (20)
Other
- Rambam Medical Center - Haifa
- Shaare Zedek Medical Center - Jerusalem
- Rabin Medical Center-Beilinson Campus - Petah Tikva
- Sheba Medical Center - Ramat Gan
- Tel Aviv Sourasky Medical Center - Tel Aviv
- National Cancer Center - Gyeonggi-do
California
- UCSF Helen Diller Family CCC - San Francisco
- Stanford Cancer Institute - Stanford
- Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center - Torrance
- Wellness Oncology and Hematology - Main Office - West Hills
Pennsylvania
- UPMC Pinnacle Health System - Harrisburg
- Thomas Jefferson University Hospital - Philadelphia
- Univ of Pittsburgh Sch of Med - Pittsburgh
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Northwest Georgia Oncology Centers PC - Marietta - Marietta
Maryland
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Baltimore
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2017-12-22 |
| Est. Completion | 2024-09-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03280563
The ClinicalTrials.gov registry entry for NCT03280563 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 568-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (75% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT03280563 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT03280563 about?
NCT03280563 is a clinical study titled "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer". This study is designed to evaluate the efficacy, safety, and pharmacokinetics of several immunotherapy-based combination treatments in participants with inoperable locally advanced or metastatic HR-positive, HER2-negative breast cancer who have progressed during or following treatment with a cyclin-...
What is the current status of trial NCT03280563?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2017-12-22. Estimated completion is 2024-09-26.
What conditions does trial NCT03280563 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT03280563?
The interventions under investigation include: Bevacizumab (DRUG), Exemestane (DRUG), Fulvestrant (DRUG), Entinostat (DRUG), Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody (DRUG).
Who is sponsoring clinical trial NCT03280563?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03280563 being conducted?
This trial has 20 study locations across Alabama, California, Georgia, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.